On 16 November, the Brigham and Women’s Hospital, a world-class academic medical center based in Boston, Massachusetts, announced the start of a clinical trial that will test the efficacy and safety of a new vaccine delivered nasally for Alzheimer’s disease (AD). This will be the first human trial of a nasal vaccine for AD and represents the culmination of nearly 20 years of research led at the Brigham and Women’s Hospital.
The vaccine uses the immune modulator Protollin, an investigational intranasal agent that stimulates the immune system. Protollin is designed to activate white blood cells found in the lymph nodes on the sides and back of the neck to migrate to the brain and trigger clearance of beta amyloid plaques. The clinical trial will be a single ascending dose study with 16 participants with early and symptomatic AD. who will receive two doses of the nasal vaccine one week apart. The primary objective of the trial will be to determine the safety and tolerability of the nasal vaccine. The effect of nasal Protollin on participants’ immune response, including its effects on white blood cells, will also be measured.
https://www.brighamandwomens.org/about-bwh/newsroom/press-releases-detail?id=4029
